Safety, efficacy and pharmacokinetics of palivizumab in off-label neonates, infants, and young children at risk for serious respiratory syncytial virus infection: a multicenter phase II clinical trial

BACKGROUND: Pediatric patients with certain rare diseases are at increased risk of severe respiratory syncytial virus (RSV) infection. However, the prophylactic use of anti-RSV antibody (palivizumab) in these patients is not indicated at present in Japan. METHODS: This first-in-the-world multicenter...

Descripción completa

Detalles Bibliográficos
Autores principales: Mori, Masaaki, Yoshizaki, Kanako, Watabe, Shinichi, Ishige, Mika, Hinoki, Akinari, Kondo, Takuya, Taguchi, Tomoaki, Hasegawa, Hisaya, Hatata, Tomoko, Tanuma, Naoyuki, Kirino, Kosuke, Hirakawa, Akihiro, Naruto, Takuya, Imai, Minoru, Koike, Ryuji, Hosoi, Kenichiro, Kusuda, Satoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10405310/
https://www.ncbi.nlm.nih.gov/pubmed/37554997
http://dx.doi.org/10.1016/j.lanwpc.2023.100847

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10405310/
https://www.ncbi.nlm.nih.gov/pubmed/37554997
http://dx.doi.org/10.1016/j.lanwpc.2023.100847

Ejemplares similares